As the healthcare industry continues to evolve, the demand for reliable and innovative diagnostic solutions has never been more pressing. Tianlong, a domestic pioneer in the field of nucleic acid testing instruments and reagents, has been at the forefront of this revolution, delivering cutting-edge products and total solutions that are optimizing the landscape of PCR diagnostics.
Pioneering Nucleic Acid Testing Technologies
Established in 1997, Tianlong has dedicated itself to the relentless pursuit of research and development in the realm of nucleic acid testing. With a focus on innovation, the company has developed a comprehensive portfolio of products, including nucleic acid extractors (magnetic beads method), PCR thermal cyclers, real-time PCR systems, and automatic nucleic acid workstations, all backed by a wide range of compatible extraction and detection kits.
Tianlong’s commitment to excellence is evident in the company’s impressive track record. Their products have obtained more than 70 China NMPA approvals and over 120 international approvals and certifications in the European Union, the United States, South Korea, and beyond. This global recognition has enabled Tianlong to expand its reach, with its products being marketed in more than 100 countries and regions worldwide.
Empowering Clinical Diagnostics and Epidemic Response
Tianlong’s PCR diagnostic solutions have found widespread application across various sectors, including clinical diagnostics, epidemic prevention and control, food safety, and scientific research. During the COVID-19 pandemic and other major outbreaks, such as avian influenza and Ebola, Tianlong’s products and dedicated team have played a pivotal role in strengthening disease prevention and control efforts.
Tianlong’s commitment to innovation and quality has earned the trust of healthcare professionals and institutions worldwide. Their products are renowned for their reliability, accuracy, and ease of use, making them a preferred choice for clinical laboratories, research facilities, and public health agencies.
Conclusion
As the healthcare landscape continues to evolve, Tianlong remains steadfast in its mission to push the boundaries of PCR diagnostics. Through ongoing research and development, the company is committed to delivering innovative solutions that address the emerging needs of the industry.
By leveraging its expertise, Tianlong is poised to play a crucial role in shaping the future of PCR diagnostics, empowering healthcare professionals and researchers to make more informed decisions, improve patient outcomes, and safeguard public health on a global scale.
